AxoGen Inc
NASDAQ:AXGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.67
15.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
AxoGen Inc
AxoGen Inc
Cash & Cash Equivalents
AxoGen Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AxoGen Inc
NASDAQ:AXGN
|
Cash & Cash Equivalents
$18.7m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
5%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash & Cash Equivalents
$1.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
55%
|
CAGR 10-Years
26%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$3.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$2.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
AxoGen Inc
Glance View
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 428 full-time employees. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.
See Also
What is AxoGen Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
18.7m
USD
Based on the financial report for Sep 30, 2024, AxoGen Inc's Cash & Cash Equivalents amounts to 18.7m USD.
What is AxoGen Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
5%
Over the last year, the Cash & Cash Equivalents growth was -40%. The average annual Cash & Cash Equivalents growth rates for AxoGen Inc have been -26% over the past three years , -5% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
